Can I Take Ashwagandha with Trazodone?

How Trazodone Works

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) approved by the FDA for major depressive disorder, though clinicians prescribe it off-label for insomnia far more often than for depression. At antidepressant doses (150 to 400 mg/day), trazodone blocks the serotonin 5-HT2A receptor and inhibits the serotonin transporter (SERT). At the lower doses used for sleep (25 to 100 mg), the 5-HT2A antagonism and histamine H1 blockade dominate, producing sedation without strong reuptake inhibition 1.

Metabolism and Half-Life

Trazodone undergoes hepatic metabolism primarily through CYP3A4, with a secondary contribution from CYP2D6 2. Its active metabolite, m-chlorophenylpiperazine (mCPP), is a serotonin agonist that can contribute to anxiety and nausea at higher parent doses. The elimination half-life is 5 to 9 hours in healthy adults, extending in patients with hepatic impairment 3.

Off-Label Sleep Use

A 2017 systematic review in CNS Drugs (N = 9 RCTs, combined enrollment 812) found trazodone 50 to 100 mg improved subjective sleep quality and total sleep time without next-day cognitive impairment at those doses 1. The American Academy of Sleep Medicine conditionally recommends trazodone when cognitive-behavioral therapy for insomnia (CBT-I) is insufficient 4.

How Ashwagandha Works

Ashwagandha (Withania somnifera) is a root extract classified as an adaptogen. Its bioactive withanolides modulate the hypothalamic-pituitary-adrenal (HPA) axis, lower serum cortisol, and show GABAergic and mild serotonergic activity in preclinical models 5.

Cortisol and Stress Reduction

A 2012 double-blind RCT (N = 64) published in the Indian Journal of Psychological Medicine found that 300 mg twice daily of a standardized root extract (KSM-66) reduced serum cortisol by 27.9% versus placebo over 60 days (P<0.001) 6. A 2022 meta-analysis of 12 RCTs (N = 1,002) confirmed a statistically significant cortisol reduction with a standardized mean difference of −0.51 (95% CI: −0.75 to −0.28) 7.

Thyroid Hormone Stimulation

In a 2018 pilot study of 50 subclinical hypothyroid adults, ashwagandha 600 mg/day significantly raised serum T4 levels toward normal after 8 weeks compared with placebo 8. This thyroid-stimulating property is relevant when combined with any serotonergic drug, because thyroid hormone amplifies central serotonin sensitivity.

Sleep Data

A 2020 RCT (N = 150) in the Journal of Ethnopharmacology reported that ashwagandha root extract 120 mg (standardized to ≥42% withanolide glycosides) improved sleep onset latency by 4 minutes and sleep quality scores by 72% versus placebo over 6 weeks (P<0.05) 9.

Where the Interaction Happens

The ashwagandha-trazodone interaction has both pharmacokinetic and pharmacodynamic components. Neither alone reaches the threshold for a contraindication, but layered together they warrant clinical attention.

Pharmacokinetic Overlap: CYP3A4 Competition

Trazodone relies on CYP3A4 for clearance 2. In vitro data show withaferin A, a key withanolide, inhibits CYP3A4 at high concentrations 10. At typical supplement doses (300 to 600 mg/day), the clinical magnitude of this inhibition is unclear because human pharmacokinetic interaction studies have not been published. The theoretical risk is a modest increase in trazodone plasma levels, which could intensify sedation and orthostatic hypotension.

Pharmacodynamic Overlap: Serotonin

Trazodone blocks 5-HT2A receptors and inhibits SERT 1. Ashwagandha's withanolides show serotonin-receptor modulation in rodent models, with one study reporting increased serotonin levels in the prefrontal cortex after 21 days of dosing 5. Although ashwagandha alone is unlikely to cause serotonin syndrome, adding it to a SARI shifts the pharmacodynamic balance. The risk rises if a patient also takes an SSRI, SNRI, or triptan.

Pharmacodynamic Overlap: Sedation

Both agents promote sleep. Trazodone does so through H1 and 5-HT2A antagonism; ashwagandha through GABAergic activity and cortisol suppression 6. The additive sedation may be welcome at bedtime but problematic if the patient drives or operates machinery early the next morning, especially during dose titration.

Thyroid Axis Interaction

Ashwagandha can raise T4 8. Elevated thyroid hormone increases the density of 5-HT2A receptors in the CNS 11. Because trazodone's therapeutic action centers on 5-HT2A blockade, a shift in receptor density could alter its efficacy or side-effect profile. Patients with borderline or overt hyperthyroidism face the highest risk.

Who Should Avoid the Combination

Not everyone needs to avoid ashwagandha while on trazodone. Certain clinical profiles, however, tip the risk-benefit ratio toward avoidance.

High Serotonergic Load

Patients who already take an SSRI (e.g., sertraline) or an SNRI (e.g., venlafaxine) alongside trazodone for sleep carry a higher baseline serotonin tone. Adding ashwagandha introduces a third serotonergic influence. The Natural Medicines Comprehensive Database rates the interaction of ashwagandha with serotonergic drugs as "moderate," advising clinical monitoring 12.

Thyroid Disorders

Anyone with Graves' disease, uncontrolled hyperthyroidism, or subclinical hyperthyroidism should not add ashwagandha without endocrinologist approval. The T4-raising effect documented by Sharma et al. (2018) could push thyroid levels into a symptomatic range and alter trazodone's receptor-level pharmacology 8.

Hepatic Impairment

Both ashwagandha and trazodone undergo hepatic metabolism. Cases of clinically apparent liver injury after ashwagandha use have been reported in the NIH LiverTox database 13. Patients with baseline ALT or AST elevations above 2× the upper limit of normal should avoid the combination until liver function normalizes.

Dose-Separation and Timing Strategy

If your prescriber approves the combination, dose timing matters. The goal is to minimize peak-plasma overlap at CYP3A4 and to spread the sedative load.

Recommended Schedule

Take ashwagandha with a morning or early-afternoon meal (300 mg of root extract). Take trazodone at bedtime as prescribed. This creates a separation of roughly 8 to 12 hours, well beyond ashwagandha's Tmax of 2 to 3 hours and past the peak of its cortisol-lowering effect 7.

Why Not Both at Bedtime?

Stacking both agents at the same time compresses two sedative peaks into one window. Orthostatic hypotension risk increases because trazodone's alpha-1 blockade coincides with ashwagandha's mild vasodilatory activity noted in preclinical data 14. Morning ashwagandha dosing also preserves the cortisol-lowering benefit during the waking hours when stress is physiologically highest.

Dose Ceiling

When combining ashwagandha with trazodone, a conservative dose ceiling applies. Limit ashwagandha to 300 mg/day of standardized root extract (≥5% withanolides) during the first 8 weeks and assess tolerability before increasing to 600 mg/day. Keep trazodone at the lowest effective insomnia dose, typically 25 to 50 mg, and avoid exceeding 100 mg without reassessing the combination's risk profile.

Monitoring Protocol

Routine lab monitoring catches problems before they become symptomatic. The monitoring schedule below applies to patients taking both agents concurrently for longer than 30 days.

Baseline Labs (Before Starting)

Draw a comprehensive metabolic panel (CMP), TSH with free T4, and an AM cortisol within 30 days of starting ashwagandha alongside trazodone. The CMP establishes liver enzyme baselines that matter for both drugs 3.

Follow-Up Schedule

Recheck TSH and free T4 at 8 weeks, then every 6 months. A rising free T4 above the reference range warrants stopping ashwagandha 8. Recheck hepatic enzymes at 12 weeks. If ALT remains below 2× ULN, extend to annual monitoring. Track AM cortisol annually; a level below 3 µg/dL may indicate excessive HPA suppression requiring ashwagandha dose reduction 15.

Symptom Monitoring

Watch for excessive daytime sedation, dizziness on standing, unexplained tachycardia (thyroid-related), and gastrointestinal distress. Serotonin syndrome signs (clonus, hyperthermia, agitation) are rare at these doses but require emergency evaluation if they occur 16.

What to Do If You Are Already Taking Both

Many patients start ashwagandha on their own before discussing it with their prescriber. If you are already combining the two agents and feel well, abrupt discontinuation is unnecessary.

Step 1: Disclose to Your Prescriber

Bring the exact product label (brand, dose, withanolide percentage) to your next appointment. Supplement standardization varies widely, and the interaction risk scales with withanolide content 5.

Step 2: Get Baseline Labs

Request TSH with free T4, CMP, and AM cortisol. These establish whether the combination has already shifted thyroid or hepatic markers.

Step 3: Adjust Timing

If you have been taking both at bedtime, shift ashwagandha to the morning. Most patients notice no reduction in sleep quality because ashwagandha's cortisol effect persists for 8 or more hours after dosing 6.

Step 4: Re-Evaluate at 8 Weeks

If labs are normal and symptoms are absent, the combination can continue under periodic monitoring. If TSH is suppressed or free T4 is elevated, taper ashwagandha over 2 weeks rather than stopping abruptly.

Testosterone and Cortisol: Secondary Considerations

Ashwagandha has been studied for testosterone enhancement in men. A 2019 RCT (N = 57) in the American Journal of Men's Health found that 300 mg twice daily of KSM-66 increased total testosterone by 14.7% versus placebo over 8 weeks 17. Trazodone, by contrast, is occasionally associated with sexual side effects including priapism (rare, estimated at 1 in 10,000 prescriptions) according to its FDA label 3. The testosterone-raising effect of ashwagandha is unlikely to worsen priapism risk, but clinicians should document baseline sexual function when the two are co-prescribed.

Cortisol modulation also intersects with trazodone's pharmacology. Chronic cortisol elevation downregulates serotonin receptors 18. By lowering cortisol, ashwagandha may upregulate receptor density and theoretically potentiate trazodone's serotonergic effects. This is speculative but mechanistically plausible, and it supports the rationale for conservative dosing when the two are combined.

Evidence Gaps

No published human pharmacokinetic study has directly measured ashwagandha's effect on trazodone plasma concentrations. The CYP3A4 inhibition data come from in vitro assays using isolated withanolides at concentrations that may not reflect oral supplement dosing 10. The serotonergic interaction is extrapolated from rodent models and case-reasoning rather than controlled human trials. Until a formal interaction study is completed, the clinical recommendations in this article follow a precautionary approach consistent with the Natural Medicines Comprehensive Database guidance.

A 2021 systematic review of ashwagandha safety across 69 clinical studies (N = 3,509 total participants) reported a side-effect profile similar to placebo, with mild GI disturbance as the most common complaint 19. No serotonin syndrome cases were documented in any study, though none specifically enrolled patients on SARIs.

Patients who take ashwagandha 300 mg in the morning with trazodone 25 to 50 mg at bedtime, maintain normal TSH, and report no excessive sedation fall into the lowest-risk category for this combination.